• Free for qualified executives and consultants to industry

  • Receive quarterly issues of Area Development Magazine and special market report and directory issues


WuXi PharmaTech Begins Construction On Manufacturing Facility In Philadelphia, Pennsylvania

WuXi PharmaTech, a pharmaceutical, biotechnology, and medical device R&D services company with operations in China and the United States, has broken ground on a new facility in Philadelphia, Pennsylvania, designed for the manufacture of cell therapies. The facility is expected to become operational in the second quarter of 2015.

The new facility will consist of 45,000 square feet of clinical and commercial manufacturing space and will supplement WuXi's existing 16,000-square-foot cGMP cell therapy manufacturing facility.

Located in the Philadelphia Navy Yard, company officials said its new facility will complement WuXi's existing facility and capabilities which include analytical chemistry, cell banking, cell characterization, molecular biology and lot release testing, thereby providing fully integrated services for cell therapies in Philadelphia.

"Cell therapies offer important treatment options, and WuXi is committed to bringing them to patients faster," said Dr. Ge Li, Chairman/CEO of PharmaTech.

The company said “this expansion will support growing customer demand with single-source contract development and cGMP manufacture capabilities for allogeneic and autologous cell-based therapeutics. The new facility will be built using advanced modular design, with flexible clean room technology, disposable equipment, and microcarrier cell culture systems.”

Exclusive Research